Analysts Set Cognition Therapeutics, Inc. (NASDAQ:CGTX) Target Price at $8.00

Shares of Cognition Therapeutics, Inc. (NASDAQ:CGTX) have received an average recommendation of “Moderate Buy” from the six ratings firms that are covering the firm, Marketbeat.com reports. Two investment analysts have rated the stock with a hold recommendation and four have issued a buy recommendation on the company. The average twelve-month price target among analysts that have issued a report on the stock in the last year is $8.00.

A number of research analysts have recently commented on CGTX shares. B. Riley reissued a “neutral” rating and set a $1.00 price target (down from $5.00) on shares of Cognition Therapeutics in a report on Tuesday, August 6th. Cantor Fitzgerald cut shares of Cognition Therapeutics from an “overweight” rating to a “neutral” rating in a research note on Tuesday, July 30th. HC Wainwright dropped their price target on shares of Cognition Therapeutics from $7.00 to $5.00 and set a “buy” rating on the stock in a research report on Monday, August 12th. Finally, Rodman & Renshaw reiterated a “buy” rating and issued a $14.00 price objective on shares of Cognition Therapeutics in a report on Tuesday, July 2nd.

Hedge Funds Weigh In On Cognition Therapeutics

Hedge funds have recently made changes to their positions in the business. Tocqueville Asset Management L.P. bought a new stake in Cognition Therapeutics during the first quarter worth approximately $47,000. Levin Capital Strategies L.P. acquired a new stake in shares of Cognition Therapeutics during the 1st quarter valued at $55,000. Bangor Savings Bank boosted its stake in shares of Cognition Therapeutics by 41.6% during the 2nd quarter. Bangor Savings Bank now owns 34,019 shares of the company’s stock worth $56,000 after acquiring an additional 10,000 shares in the last quarter. Twin Focus Capital Partners LLC acquired a new position in shares of Cognition Therapeutics in the 4th quarter worth $173,000. Finally, Mercer Global Advisors Inc. ADV raised its position in shares of Cognition Therapeutics by 33.4% during the second quarter. Mercer Global Advisors Inc. ADV now owns 95,951 shares of the company’s stock worth $159,000 after purchasing an additional 24,050 shares during the period. Institutional investors and hedge funds own 43.35% of the company’s stock.

Cognition Therapeutics Stock Up 6.4 %

Cognition Therapeutics stock opened at $0.45 on Thursday. Cognition Therapeutics has a 52-week low of $0.34 and a 52-week high of $2.95. The firm has a market capitalization of $17.94 million, a price-to-earnings ratio of -0.49 and a beta of 1.36. The firm has a 50-day moving average price of $0.57 and a two-hundred day moving average price of $1.42.

Cognition Therapeutics (NASDAQ:CGTX) last issued its quarterly earnings data on Thursday, August 8th. The company reported ($0.18) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.22) by $0.04. During the same period last year, the company earned ($0.16) EPS. Research analysts expect that Cognition Therapeutics will post -0.96 earnings per share for the current year.

Cognition Therapeutics Company Profile

Cognition Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is CT1812, an orally delivered molecule modulator designed to penetrate the blood-brain barrier and bind selectively to the S2R complex, which is in Phase 2 clinical trial for the treatment of Alzheimer's disease, as well as geographic atrophy secondary to dry age-related macular degeneration and synucleinopathies, such as dementia with Lewy bodies.